Literature DB >> 22207755

The ubiquitin regulatory X (UBX) domain-containing protein TUG regulates the p97 ATPase and resides at the endoplasmic reticulum-golgi intermediate compartment.

Charisse M Orme1, Jonathan S Bogan.   

Abstract

p97/VCP is a hexameric ATPase that is coupled to diverse cellular processes, such as membrane fusion and proteolysis. How p97 activity is regulated is not fully understood. Here we studied the potential role of TUG, a widely expressed protein containing a UBX domain, to control mammalian p97. In HEK293 cells, the vast majority of TUG was bound to p97. Surprisingly, the TUG UBX domain was neither necessary nor sufficient for this interaction. Rather, an extended sequence, comprising three regions of TUG, bound to the p97 N-terminal domain. The TUG C terminus resembled the Arabidopsis protein PUX1. Similar to the previously described action of PUX1 on AtCDC48, TUG caused the conversion of p97 hexamers into monomers. Hexamer disassembly was stoichiometric rather than catalytic and was not greatly affected by the p97 ATP-binding state or by TUG N-terminal regions in vitro. In HeLa cells, TUG localized to the endoplasmic reticulum-to-Golgi intermediate compartment and endoplasmic reticulum exit sites. Although siRNA-mediated TUG depletion had no marked effect on total ubiquitylated proteins or p97 localization, TUG overexpression caused an accumulation of ubiquitylated substrates and targeted both TUG and p97 to the nucleus. A physiologic role of TUG was revealed by siRNA-mediated depletion, which showed that TUG is required for efficient reassembly of the Golgi complex after brefeldin A removal. Together, these data support a model in which TUG controls p97 oligomeric status at a particular location in the early secretory pathway and in which this process regulates membrane trafficking in various cell types.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22207755      PMCID: PMC3307297          DOI: 10.1074/jbc.M111.284232

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  77 in total

1.  Ubx4 modulates cdc48 activity and influences degradation of misfolded proteins of the endoplasmic reticulum.

Authors:  Sven M Alberts; Caroline Sonntag; Antje Schäfer; Dieter H Wolf
Journal:  J Biol Chem       Date:  2009-04-09       Impact factor: 5.157

2.  Ubxd1 is a novel co-factor of the human p97 ATPase.

Authors:  Louise Madsen; Katrine M Andersen; Søren Prag; Torben Moos; Colin A Semple; Michael Seeger; Rasmus Hartmann-Petersen
Journal:  Int J Biochem Cell Biol       Date:  2008-07-05       Impact factor: 5.085

3.  UBXD1 binds p97 through two independent binding sites.

Authors:  Maximilian Kern; Vanesa Fernandez-Sáiz; Zasie Schäfer; Alexander Buchberger
Journal:  Biochem Biophys Res Commun       Date:  2009-01-25       Impact factor: 3.575

Review 4.  Emerging new roles of GM130, a cis-Golgi matrix protein, in higher order cell functions.

Authors:  Nobuhiro Nakamura
Journal:  J Pharmacol Sci       Date:  2010-03-02       Impact factor: 3.337

5.  Crystallization and preliminary X-ray crystallographic analysis of the N domain of p97/VCP in complex with the UBX domain of FAF1.

Authors:  Hwa Young Shin; Wonchull Kang; Sang Yoon Lee; Jin Kuk Yang
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2009-12-25

6.  UBXD1 is a VCP-interacting protein that is involved in ER-associated degradation.

Authors:  Masami Nagahama; Machi Ohnishi; Yumiko Kawate; Takayuki Matsui; Hitomi Miyake; Keizo Yuasa; Katsuko Tani; Mitsuo Tagaya; Akihiko Tsuji
Journal:  Biochem Biophys Res Commun       Date:  2009-03-09       Impact factor: 3.575

7.  UBXD4, a UBX-containing protein, regulates the cell surface number and stability of alpha3-containing nicotinic acetylcholine receptors.

Authors:  Khosrow Rezvani; Yanfen Teng; Yaping Pan; John A Dani; Jon Lindstrom; Eduardo A García Gras; J Michael McIntosh; Mariella De Biasi
Journal:  J Neurosci       Date:  2009-05-27       Impact factor: 6.167

8.  p97/valosin-containing protein (VCP) is highly modulated by phosphorylation and acetylation.

Authors:  Chiho Mori-Konya; Naruyoshi Kato; Ryota Maeda; Kunihiko Yasuda; Naoki Higashimae; Masakatsu Noguchi; Masaaki Koike; Yoko Kimura; Hiroshi Ohizumi; Seiji Hori; Akira Kakizuka
Journal:  Genes Cells       Date:  2009-04       Impact factor: 1.891

9.  Intracellular retention and insulin-stimulated mobilization of GLUT4 glucose transporters.

Authors:  Bradley R Rubin; Jonathan S Bogan
Journal:  Vitam Horm       Date:  2009       Impact factor: 3.421

10.  AAA ATPase p97/VCP: cellular functions, disease and therapeutic potential.

Authors:  Neeraj Vij
Journal:  J Cell Mol Med       Date:  2008-08-09       Impact factor: 5.310

View more
  22 in total

1.  Endoproteolytic cleavage of TUG protein regulates GLUT4 glucose transporter translocation.

Authors:  Jonathan S Bogan; Bradley R Rubin; Chenfei Yu; Michael G Löffler; Charisse M Orme; Jonathan P Belman; Leah J McNally; Mingming Hao; James A Cresswell
Journal:  J Biol Chem       Date:  2012-05-18       Impact factor: 5.157

2.  Acetylation of TUG protein promotes the accumulation of GLUT4 glucose transporters in an insulin-responsive intracellular compartment.

Authors:  Jonathan P Belman; Rachel R Bian; Estifanos N Habtemichael; Don T Li; Michael J Jurczak; Abel Alcázar-Román; Leah J McNally; Gerald I Shulman; Jonathan S Bogan
Journal:  J Biol Chem       Date:  2015-01-05       Impact factor: 5.157

Review 3.  Regulation of molecular chaperones through post-translational modifications: decrypting the chaperone code.

Authors:  Philippe Cloutier; Benoit Coulombe
Journal:  Biochim Biophys Acta       Date:  2013-02-28

4.  Valosin-containing protein (VCP)-Adaptor Interactions are Exceptionally Dynamic and Subject to Differential Modulation by a VCP Inhibitor.

Authors:  Liang Xue; Emily E Blythe; Elyse C Freiberger; Jennifer L Mamrosh; Alexander S Hebert; Justin M Reitsma; Sonja Hess; Joshua J Coon; Raymond J Deshaies
Journal:  Mol Cell Proteomics       Date:  2016-07-12       Impact factor: 5.911

Review 5.  A proteolytic pathway that controls glucose uptake in fat and muscle.

Authors:  Jonathan P Belman; Estifanos N Habtemichael; Jonathan S Bogan
Journal:  Rev Endocr Metab Disord       Date:  2014-03       Impact factor: 6.514

6.  Enhanced fasting glucose turnover in mice with disrupted action of TUG protein in skeletal muscle.

Authors:  Michael G Löffler; Andreas L Birkenfeld; Katerina M Philbrick; Jonathan P Belman; Estifanos N Habtemichael; Carmen J Booth; Carlos M Castorena; Cheol Soo Choi; Francois R Jornayvaz; Brandon M Gassaway; Hui-Young Lee; Gregory D Cartee; William Philbrick; Gerald I Shulman; Varman T Samuel; Jonathan S Bogan
Journal:  J Biol Chem       Date:  2013-06-06       Impact factor: 5.157

7.  A newly uncovered group of distantly related lysine methyltransferases preferentially interact with molecular chaperones to regulate their activity.

Authors:  Philippe Cloutier; Mathieu Lavallée-Adam; Denis Faubert; Mathieu Blanchette; Benoit Coulombe
Journal:  PLoS Genet       Date:  2013-01-17       Impact factor: 5.917

8.  Human ASPL/TUG interacts with p97 and complements the proteasome mislocalization of a yeast ubx4 mutant, but not the ER-associated degradation defect.

Authors:  Louise Madsen; Karen Molbæk; Ida B Larsen; Sofie V Nielsen; Esben G Poulsen; Peter S Walmod; Kay Hofmann; Michael Seeger; Chen-Ying Chien; Rey-Huei Chen; Franziska Kriegenburg; Rasmus Hartmann-Petersen
Journal:  BMC Cell Biol       Date:  2014-07-31       Impact factor: 4.241

9.  Lysine Methylation of the Valosin-Containing Protein (VCP) Is Dispensable for Development and Survival of Mice.

Authors:  Markus Fusser; Stefan Kernstock; Vinay Kumar Aileni; Wolfgang Egge-Jacobsen; Pål Ø Falnes; Arne Klungland
Journal:  PLoS One       Date:  2015-11-06       Impact factor: 3.240

10.  Structural Details of Ufd1 Binding to p97 and Their Functional Implications in ER-Associated Degradation.

Authors:  Le Thi My Le; Wonchull Kang; Ji-Yun Kim; Oanh Thi Tu Le; Sang Yoon Lee; Jin Kuk Yang
Journal:  PLoS One       Date:  2016-09-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.